醫療

Peanut allergy treatment raises concerns over the potential cost

Having a severe food allergy is brutal. Up to now, all sufferers could do was practice total avoidance — bringing their own food to parties, begging airlines not to serve peanuts — and pray that they could whip out their epinephrine injector in time if something went wrong.

That’s why research sponsored by Aimmune Therapeutics and published this week in the New England Journal of Medicine caused a stir. Trials involving nearly 500 children with severe peanut allergies had successfully desensitised two-thirds of those who completed the trial. After one year of treatment, they could eat the equivalent of three to four peanuts.

The company plans to file an application for its product — which involves capsules filled with increasing doses of peanut protein — with the US Food and Drug Administration next month and start the EU approval process next year.

您已閱讀23%(859字),剩餘77%(2861字)包含更多重要資訊,訂閱以繼續探索完整內容,並享受更多專屬服務。
版權聲明:本文版權歸FT中文網所有,未經允許任何單位或個人不得轉載,複製或以任何其他方式使用本文全部或部分,侵權必究。
設置字型大小×
最小
較小
默認
較大
最大
分享×